中文
BioGeometry Secures Hundreds of Millions in Strategic Financing to Pioneer Bio AI World Models
Recently, BioGeometry announced the completion of a new round of strategic financing, raising hundreds of millions of RMB. This round
News
Epitope in, antibody out: GeoFlow-V3 pushes the limit for efficient de novo antibody design
For the first time, GeoFlow V3 unifies generation, evaluation and in silico evolution of antibody binders, significantly improving their bind rates to 15.5%, 50x higher than SOTA methods in 2024.
Case | 21x Performance Boost: BioGeometry Helps Vazyme Achieve Breakthrough in IVD Enzyme Optimization
BioGeometry has successfully completed a protein engineering project for a key IVD reagent enzyme, delivering results to Nanjing Novozan Biotechnology Co., Ltd.
Strategic Partnership | BioGeometry Collaborates with Harworld to Build a New Paradigm of AI-Powered Cell Factories
, BioGeometry and Nanning Harworld Biology held a strategic cooperation signing ceremony for “AI-Driven Synthetic Biology to Accelerate Cell Factory Development.”
Awards | BioGeometry Named in Top10 of 2025 Global Biomanufacturing Conference, Pioneering Next-Gen Biomanufacturing
BioGeometry was honored “Top 10 Biomanufacturing Potential Unicorns” and “Top 10 Biomanufacturing Platform Services”
Introducing GeoFlow V2: Next-Generation Protein Foundation Model Unifying Structure Prediction and De Novo Design
Releasing GeoFlow V2, the world’s first unified atomic foundation model for protein design.
Load More